Estrogen-Progestagen Menopausal Hormone Therapy and Breast Cancer: Does Delay From Menopause Onset to Treatment Initiation Influence Risks?
Estrogen-Progestagen Menopausal Hormone Therapy and Breast Cancer: Does Delay From Menopause Onset to Treatment Initiation Influence Risks?
复制标题
DOI：
10.1200/jco.2008.21.6432
复制
发表时间：
2009-11-01
影响因子：
45.3
通讯作者：
Clavel-Chapelon, Francoise
中科院分区：
文献类型：
--
作者：
Fournier, Agnes;Mesrine, Sylvie;Clavel-Chapelon, Francoise
目的探讨雌激素-孕激素绝经激素治疗(EP-MHT)与乳腺癌风险的关系是否因绝经开始至治疗开始的时间不同而不同。参与者与方法1992-2005年间，在法国E3N队列中的53,310名绝经后妇女中发现了1,726例浸润性乳腺癌，平均随访时间为8.1年。结果在最近使用EP-MHT的患者中，乳腺癌的风险因开始治疗的时间不同而不同。这种变化仅限于较短的使用时间(
PurposeTo investigate whether the relation between estrogen-progestagen menopausal hormone therapy (EP-MHT) and breast cancer risk varies according to the delay between menopause onset and treatment initiation.Participants and MethodsBetween 1992 and 2005, 1,726 invasive breast cancers were identified among 53,310 postmenopausal women from the French E3N cohort (mean duration of follow-up, 8.1 years). Hazard ratios (HRs) and CIs were estimated using Cox models, with MHT never users as the reference.ResultsAmong recent users of EP-MHT, the risk of breast cancer varied according to the timing of treatment initiation. This variation was confined to short durations of use (